Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 1 288 B
EBIT 2018 220 B
Net income 2018 186 B
Finance 2018 391 B
Yield 2018 2,49%
Sales 2019 1 287 B
EBIT 2019 249 B
Net income 2019 196 B
Finance 2019 470 B
Yield 2019 2,58%
P/E ratio 2018 15,57
P/E ratio 2019 14,97
EV / Sales2018 2,02x
EV / Sales2019 1,96x
Capitalization 2 992 B
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
09/21 PFIZER : and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Tr..
09/15 PFIZER : Astellas Announce Positive Top-Line Results From Phase 3 Prosper Trial ..
09/15 ASTELLAS PHARMA : U.S. FDA Accepts for Review Astellas' Supplemental New Drug Ap..
09/14 ASTELLAS PHARMA : Announces Launch of 'Keep on Dancing' Sweepstakes
09/14 ASTELLAS PHARMA : Reports on Immunosuppressive Agents Findings from Astellas Pha..
09/13 ASTELLAS PHARMA : U.S. FDA Accepts for Review Astellas' Supplemental New Drug Ap..
09/11 ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
09/08 ASTELLAS PHARMA : Announces Launch of 'Keep on Dancing' Sweepstakes
09/04 ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
09/01 ASTELLAS PHARMA : Astella Announces Status of Acquisition of Own Shares (pdf 311..
More news
Sector news : Pharmaceuticals - NEC
09:36a SHANGHAI PHARMACEUTICALS : CVC, others explore sale of drugmaker Alvogen - Bloom..
09/25 European shares stay near highs as Merkel hangs on to power
09/25 Lufthansa names former CFO Kley as new chairman
09/25 ALLERGAN : boosts shares with $2 billion buyback
09/24 SAP to buy customer management software firm Gigya
More sector news : Pharmaceuticals - NEC
Latest Tweets
07:01pWorking Mother Magazine names Astellas among 100 best companies in the US acr.. 
09/15Pfizer, Astellas Show Positive Results from Prostate Cancer Trial -  
09/14#ovariancancer Pfizer Astellas eye wider market for prostate cancer drug: Xta.. 
09/14#Pfizer, #Astellas prostate cancer drug clears late-stage trial
8
09/14#ovariancancer Astellas Pfizer's Prostate Cancer Drug Hits LateStage Trial Go.. 
More tweets
Qtime:18
News from SeekingAlpha
09/15 3 THINGS IN BIOTECH YOU SHOULD LEARN : September 15, 2017
09/14 Xtandi/ADT combo extends survival in late-stage prostate cancer study
09/13 FDA accepts Astellas' marketing application Myrbetriq/VESIcare combo for OAB
09/01 Astellas Changing Its Approach, But Investors Are Skeptical
08/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 24, 2017
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 521  JPY
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Yoshihiko Hatanaka President, CEO & Representative Director
Yasumasa Masuda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Yoshiro Miyokawa Representative Director & Executive Vice President
Hironobu Yasuda Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC-11.07%26 819
JOHNSON & JOHNSON14.04%352 060
NOVARTIS12.62%226 442
ROCHE HOLDING LTD.6.62%222 309
PFIZER10.75%211 467
MERCK AND COMPANY10.72%177 769